Human papillomavirus vaccination at the first opportunity: An overview

Robert A. Bednarczyk, Noel T. Brewer, Melissa B. Gilkey, Sherri Zorn, Rebecca B. Perkins, Kristin Oliver, Debbie Saslow

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


The Advisory Committee on Immunization Practices (ACIP) has recommended human papillomavirus (HPV) vaccination for adolescents in the United States since 2006. Though recommended at a similar time to the routine recommendations for adolescent tetanus, diphtheria, and acellular pertussis vaccination (Tdap) and quadrivalent meningococcal vaccination (MCV4), HPV vaccine uptake has consistently lagged behind these other adolescent vaccines. The ACIP recommends HPV vaccination at 11–12 y, with vaccination starting at 9 y of age included as an option that is routinely encouraged by the American Academy of Pediatrics and American Cancer Society. To support efforts to increase HPV vaccination at the first opportunity, this commentary summarizes the current HPV vaccination recommendations and available evidence regarding HPV vaccination starting at 9 y–including recent studies and trials documenting the effectiveness of HPV vaccination at 9 in supporting vaccine series completion, while providing future directions for research and implementation to improve HPV vaccination.

Original languageEnglish
Article number2213603
JournalHuman Vaccines and Immunotherapeutics
Issue number1
StatePublished - 2023


  • HPV
  • HPV vaccination
  • Human papillomavirus
  • adolescent
  • vaccination recommendations


Dive into the research topics of 'Human papillomavirus vaccination at the first opportunity: An overview'. Together they form a unique fingerprint.

Cite this